AR070234A1 - Compuestos que comprenden un grupo ciclobutoxi - Google Patents
Compuestos que comprenden un grupo ciclobutoxiInfo
- Publication number
- AR070234A1 AR070234A1 ARP090100203A ARP090100203A AR070234A1 AR 070234 A1 AR070234 A1 AR 070234A1 AR P090100203 A ARP090100203 A AR P090100203A AR P090100203 A ARP090100203 A AR P090100203A AR 070234 A1 AR070234 A1 AR 070234A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- acyl
- alkynyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 C1-6 alkyl acylamino Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000005354 acylalkyl group Chemical group 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000005251 aryl acyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 125000005253 heteroarylacyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 abstract 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 abstract 1
- 125000005281 alkyl ureido group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se relaciona con los compuestos de formula (1) que comprenden un grupo ciclobutoxi, y composiciones farmacéuticas que comprenden dichos compuestos. Estos compuestos son utiles en el tratamiento y/o prevencion de enfermedades del SNC tales como Alzheimer, deterioro cognitivo leve, trastornos de la memoria y el aprendizaje, así como obesidad, inflamacion y trastornos cardiovasculares. Reivindicacion 1: Un compuesto caracterizado por la formula (1), isomeros geométricos, enantiomeros, diastereoisomeros, sales farmacéuticamente aceptables y todas las posibles mezclas de los mismos, donde A es un grupo amino cíclico o alifático sustituido o no sustituido el cual está unido al grupo ciclobutil a través de un amino nitrogeno; A1 es CH, C-halogeno o N; B es seleccionado del grupo que consiste en heteroaril, heterocicloalquil de 5-8 miembros y cicloalquil de 5-8 miembros; X es O, S, NH o N(alquil C1-4); Y es O, S, o NH; R1 es seleccionado del grupo que comprende o consiste en sulfonil, amino, alquil C1-6, alquenil C2-6, alquinil C2-6, aril, heteroaril, cicloalquil C3-8, heterocicloalquil de 3-8 miembros, acil, alquil C1-6 aril, alquil C1-6 heteroaril, alquenil C2-6 aril, alquenil C2-6 heteroaril, alquinil C2-6 aril, alquinil C2-6 heteroaril, alquil C1-6 cicloalquil, alquil C1-6 heterocicloalquil, alquenil C2-6 cicloalquil, alquenil C2-6 heterocicloalquil, alquinil C2-6 cicloalquil, alquinil C2-6 heterocicloalquil, alcoxicarbonil, aminocarbonil, alquil C1-6 carboxi, alquil C1-6 acil, aril acil, heteroaril acil, (hetero)cicloalquil C3-8 acil, alquil C1-6 aciloxi, alquil C1-6 alcoxi, alquil C1-6 alcoxicarbonil, alquil C1-6 aminocarbonil, alquil C1-6 acilamino, acilamino, acilaminocarbonil, ureido, alquil C1-6 ureido, alquil C1-6 carbamato, alquil C1-6 amino, alquil C1-6 sulfoniloxi, alquil C1-6 sulfonil, alquil C1-6 sulfinil, alquil C1-6 sulfanil, alquil C1-6 sulfonilamino, aminosulfonil, alquil C1-6 aminosulfonil, hidroxi, alquil C1-6 hidroxi, fosfonato, alquil C1-6 fosfonato, alquil C1-6 fosfono, halogeno, ciano, carboxi, oxo, tioxo; n es igual a 0, 1, 2 o 3; R2 es seleccionado del grupo que comprende o consiste en hidrogeno, sulfonil, amino, alquil C1-6, alquenil C2-6, alquinil C2-6, aril, heteroaril, cicloalquil C3-8, heterocicloalquil de 3-8 miembros, acil, alquil C1-6 aril, alquil C1-6 heteroaril, alquenil C2-6 aril, alquenil C2-6 heteroaril, alquinil C2-6 aril, alquinil C2-6 heteroaril, alquil C1-6 cicloalquil, alquil C1-6 heterocicloalquil, alquenil C2-6 cicloalquil, alquenil C2-6 heterocicloalquil, alquinil C2-6 cicloalquil, alquinil C2-6 heterocicloalquil, alcoxicarbonil, aminocarbonil, alquil C1-6 carboxi, alquil C1-6 acil, aril acil, heteroaril acil, (hetero)cicloalquil C3-8 acil, alquil C1-6 aciloxi, alquil C1-6 alcoxi, alquil C1-6 alcoxicarbonil, alquil C1-6 aminocarbonil, alquil C1-6 acilamino, acilamino, acilaminocarbonil, ureido, alquil C1-6 ureido, alquil C1-6 carbamato, alquil C1-6 amino, alquil C1-6 sulfoniloxi, alquil C1-6 sulfonil, alquil C1-6 sulfinil, alquil C1-6 sulfanil, alquil C1-6 sulfonilamino, aminosulfonil, alquil C1-6 aminosulfonil, hidroxi, alquil C1-6 hidroxi, fosfonato, alquil C1-6 fosfonato, alquilfosfono C1-6 sustituido o no sustituido halogeno, ciano, carboxi, oxo, tioxo; m es igual a 0 o 1; y R3 es hidrogeno o alquil C1-6 o halogeno o alcoxi C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2320708P | 2008-01-24 | 2008-01-24 | |
| EP08001308 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070234A1 true AR070234A1 (es) | 2010-03-25 |
Family
ID=39490075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100203A AR070234A1 (es) | 2008-01-24 | 2009-01-23 | Compuestos que comprenden un grupo ciclobutoxi |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100292188A1 (es) |
| EP (1) | EP2238144A1 (es) |
| JP (1) | JP2011510044A (es) |
| KR (1) | KR20100121629A (es) |
| CN (1) | CN101925606A (es) |
| AR (1) | AR070234A1 (es) |
| AU (1) | AU2009207693A1 (es) |
| BR (1) | BRPI0906556A2 (es) |
| CA (1) | CA2710474A1 (es) |
| CO (1) | CO6321170A2 (es) |
| DO (1) | DOP2010000229A (es) |
| EA (1) | EA201001205A1 (es) |
| IL (1) | IL206404A0 (es) |
| MX (1) | MX2010007587A (es) |
| NZ (1) | NZ586399A (es) |
| PE (1) | PE20091883A1 (es) |
| UY (1) | UY31611A1 (es) |
| WO (1) | WO2009092764A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0712823A2 (pt) * | 2006-06-23 | 2012-07-24 | Abbott Lab | derivados de ciclopropil amina como moduladores de receptor de histamina h3 |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| US20110118275A1 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TWI522361B (zh) * | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| ES2558531T3 (es) * | 2010-09-02 | 2016-02-05 | Suven Life Sciences Limited | Compuestos de heterociclilo como ligandos de receptores de histamina H3 |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ702747A (en) | 2012-06-13 | 2017-03-31 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2900806T3 (es) | 2013-10-04 | 2022-03-18 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos |
| SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| CN104059028B (zh) * | 2014-06-06 | 2020-10-16 | 北京智博高科生物技术有限公司 | 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JP2017537940A (ja) | 2014-12-10 | 2017-12-21 | マサチューセッツ インスティテュート オブ テクノロジー | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
| JP7264642B2 (ja) | 2016-03-16 | 2023-04-25 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| FI3792260T3 (fi) * | 2018-05-08 | 2024-10-01 | Nippon Shinyaku Co Ltd | Atsabentsimidatsoliyhdisteitä ja lääkkeitä |
| MX2021000295A (es) | 2018-07-11 | 2021-03-31 | H Lee Moffitt Cancer Ct & Res | Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon. |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022551033A1 (en) | 2019-10-31 | 2023-06-14 | Escape Bio Inc | Solid forms of an s1p-receptor modulator |
| KR20220100627A (ko) | 2019-11-13 | 2022-07-15 | 니뽄 신야쿠 가부시키가이샤 | 아자벤즈이미다졸 화합물 및 의약 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2021282596A1 (en) | 2020-06-05 | 2023-01-19 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN116462627A (zh) * | 2023-04-19 | 2023-07-21 | 南京优氟医药科技有限公司 | 一种3-溴代哌啶-2,6-二酮的制备方法 |
| CN117362316A (zh) * | 2023-10-07 | 2024-01-09 | 康龙化成手性医药技术(宁波)有限公司 | 一种四氢吡咯并噻唑类化合物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008534542A (ja) * | 2005-03-31 | 2008-08-28 | ユセベ ファルマ ソシエテ アノニム | オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用 |
| US7553964B2 (en) * | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US7576110B2 (en) * | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
-
2009
- 2009-01-22 CN CN2009801029945A patent/CN101925606A/zh active Pending
- 2009-01-22 KR KR1020107018823A patent/KR20100121629A/ko not_active Withdrawn
- 2009-01-22 EA EA201001205A patent/EA201001205A1/ru unknown
- 2009-01-22 CA CA2710474A patent/CA2710474A1/en not_active Abandoned
- 2009-01-22 WO PCT/EP2009/050719 patent/WO2009092764A1/en not_active Ceased
- 2009-01-22 NZ NZ586399A patent/NZ586399A/en not_active IP Right Cessation
- 2009-01-22 MX MX2010007587A patent/MX2010007587A/es not_active Application Discontinuation
- 2009-01-22 EP EP09703770A patent/EP2238144A1/en not_active Withdrawn
- 2009-01-22 AU AU2009207693A patent/AU2009207693A1/en not_active Abandoned
- 2009-01-22 PE PE2009000073A patent/PE20091883A1/es not_active Application Discontinuation
- 2009-01-22 JP JP2010543497A patent/JP2011510044A/ja not_active Withdrawn
- 2009-01-22 BR BRPI0906556-3A patent/BRPI0906556A2/pt not_active IP Right Cessation
- 2009-01-22 US US12/812,719 patent/US20100292188A1/en not_active Abandoned
- 2009-01-23 AR ARP090100203A patent/AR070234A1/es unknown
- 2009-01-23 UY UY031611A patent/UY31611A1/es unknown
-
2010
- 2010-06-16 IL IL206404A patent/IL206404A0/en unknown
- 2010-07-09 CO CO10083721A patent/CO6321170A2/es not_active Application Discontinuation
- 2010-07-23 DO DO2010000229A patent/DOP2010000229A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31611A1 (es) | 2009-08-31 |
| CA2710474A1 (en) | 2009-07-30 |
| IL206404A0 (en) | 2010-12-30 |
| DOP2010000229A (es) | 2010-08-31 |
| MX2010007587A (es) | 2010-08-04 |
| JP2011510044A (ja) | 2011-03-31 |
| AU2009207693A1 (en) | 2009-07-30 |
| PE20091883A1 (es) | 2010-01-07 |
| WO2009092764A1 (en) | 2009-07-30 |
| CN101925606A (zh) | 2010-12-22 |
| NZ586399A (en) | 2011-12-22 |
| EP2238144A1 (en) | 2010-10-13 |
| CO6321170A2 (es) | 2011-09-20 |
| EA201001205A1 (ru) | 2011-04-29 |
| US20100292188A1 (en) | 2010-11-18 |
| BRPI0906556A2 (pt) | 2015-07-07 |
| KR20100121629A (ko) | 2010-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070234A1 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| AR081587A1 (es) | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) | |
| PE20240017A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| AR072051A1 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
| AR059201A1 (es) | Compuestos citotoxicos derivados de tomaimicina | |
| UY32025A (es) | Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones. | |
| AR086590A1 (es) | Compuestos de ciclohexanona y herbicidas que los comprenden | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| NO20081128L (no) | 4-fenyl-6-substituerte-pyrimidin-2-karbonitrilderivater | |
| AR075249A1 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles, metodo de preparacion de los mismos e intermediarios de dicha sintesis, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer, artritis, alergias y otras enfermedades. | |
| AR054801A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o ciclico, metodos para su preparacion, composiciones farmaceuticas que las comprenden y su uso en la fabricacion de un medicamento para estimular la expresion de no sintasa endotelial | |
| AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
| PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| DE50310609D1 (de) | Cyclische amide | |
| AR074275A1 (es) | Derivados de oxoacetidina, procedimiento para su preparacion y su uso como moduladores de la melanocortina | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR077365A1 (es) | Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |